Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with SGLT2 inhibitors
SGLT2 inhibitors appear safe to use alongside lung cancer chemotherapy despite weight loss concerns, offering patients treatment flexibility.
In this retrospective analysis of 82 advanced NSCLC patients with comorbid diabetes, SGLT2 inhibitor use was associated with greater weight loss but did not worsen survival outcomes or increase major adverse events, suggesting SGLT2i can be continued safely during lung cancer systemic therapy. However, the small sample size and retrospective design limit conclusions, and the safety signal warrants prospective evaluation given the weight loss concern in cachexia-prone cancer patients.
What the study was
- Study design
- Retrospective cohort study
- Population
- Advanced NSCLC patients with type 2 diabetes receiving first-line systemic therapy
- Sample size
- 82
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- Supportive Care in Cancer
Why it surfaced
Clinically relevant question about SGLT2i safety in cancer patients; small N=82 retrospective limits conclusions; design_quality 0 (retrospective, no adjustment for confounders described).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.